All In Biotech

Drug Trial Radar · NCT06048484

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

A Phase 2, Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination With Immune Checkpoint Blockade and Radiation Therapy in Patients With Advanced PANCreatic Ductal Adenocarcinoma Who Are Candidates for Surgical Resection

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

May 10, 2024

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Gulam ManjiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arcus Biosciences, Inc.
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.

Conditions

  • Pancreatic Ductal Adenocarcinoma

Interventions

  • Stereotactic body radiotherapy (SBRT)Radiation

    SBRT 40 gray (Gy) over 5 fractions

  • ZimberelimabDrug

    240 mg intravenously (IV)

  • QuemliclustatDrug

    100 mg IV

  • EtrumadenantDrug

    150 mg orally

  • Modified FOLFIRINOXDrug

    * Oxaliplatin 85 mg per square meter IV * Irinotecan 150 mg per square meter IV * Leucovorin 400 mg per square meter IV * Fluorouracil 2400 mg per square meter IV * Pegfilgrastim injector kit (6mg subcutaneous)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the number of intratumoral CD8+ T-cellsTime frame: Perioperative

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Northwell Health R.J. Zuckerberg Cancer Center

    Lake Success, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • UNC Hospitals, The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.